A recent study shows that most early stage breast cancer patients are eligible for short course radiation therapy. ASTRO guidelines state the same.
Chemo/Large Breast Size OK for Short Course
A phase 2 trial comparing every other day to once a week Stereotactic Body Radiation Therapy (SBRT) for prostate cancer shows lower side effects with 5 treatments given once a week.
A study from Australia published in Lancet Oncology this month shows: In patients with inoperable peripherally located stage 1 NSCLC, compared with standard radiotherapy, SABR (SBRT) resulted in superior local control of the primary disease without an increase in major toxicity. The findings of this trial suggest that SABR (SBRT) should be the treatment of choice for this patient group
Short Course Radiation for Lung Cancer
Patients eligible for SBRT (Stereotactic Body Radiation Therapy) for Prostate Cancer can now access this new procedure being performed at OneDayRT. Another technological aid for performing Short Course Radiation Therapy.
A new study published in JAMA shows that Active Surveillance/ Watchful Waiting has increased for prostate cancer with low risk features. However, more surgery is being performed for high risk prostate cancer.
High-dose, high-precision radiation therapy safe and effective for kidney cancer patients with only one kidney
Treatment of renal cell carcinoma with SABR is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. SABR has been shown to be effective in treating cancers in the lung, liver and spine using substantially
higher doses of radiation delivered in a single, or just a few, treatment sessions. The abstract was presented at ASTRO 2018 by lead author Rohann J. M. Correa, MD, PhD, with London Health Sciences Center in London, Canada
ASTRO 2018: John Staffurth, MD, MB, from Cardiff University, gave an update on the progress of the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial. The five-year findings of this noninferiority trial show evidence that hypofractionation (60 Gray in 20 fractions or 57 Gray in 19 fractions) reduces long-term sexual side effects with no significant effect on bowel or urinary side effects in patients with localized prostate cancer versus a traditional treatment schedule (74 Gray in 37 fractions).
Long-term side effects similarly low for once-weekly and conventional breast radiation therapies, trial finds
ASTRO 2018 Annual Meeting: In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer, larger individual doses experienced similarly low rates of late-onset side effects as those undergoing conventional radiation therapy. The abstract, FAST phase III RCT of radiation therapy hypofractionation for treatment of early breast cancer: 10-year results (CRUKE/04/015), was presented by lead author Murray Brunt, MD, a professor of clinical oncology at University Hospitals of North Midlands and Keele University in the United Kingdom (UK), and lead author of this study. The trial was designed to assess changes in healthy breast tissue following conventional radiation treatment compared with two shorter regimens that delivered higher doses of radiation in fewer sessions.
Newly presented at the annual meeting of the American Society of Radiation Oncology (ASTRO) 2018:
In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer. The patients were treated with stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT), which is a form of high-precision cancer therapy that delivers substantially higher doses of radiation to the tumor site in just one or a few treatment sessions.
New ASTRO/ASCO/AUA guideline for early-stage prostate cancer supports use of shortened courses of radiation therapy
View “Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline” in the following journals: